Health Dictionary Find a Doctor

SV2A

Synaptic vesicle glycoprotein 2A is a ubiquitous synaptic vesicle protein that in humans is encoded by the SV2A gene.[1][2][3] The protein is targeted by the anti-epileptic drugs (anticonvulsants) levetiracetam and brivaracetam.[4] but not the chemically similar drug etiracetam

See also

See also

References

References

  1. Bajjalieh SM, Peterson K, Linial M, Scheller RH (Mar 1993). “Brain contains two forms of synaptic vesicle protein 2”. Proceedings of the National Academy of Sciences of the United States of America. 90 (6): 2150–4. doi:10.1073/pnas.90.6.2150. PMC 46043. PMID 7681585.
  2. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (Dec 1999). “Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)”. Proceedings of the National Academy of Sciences of the United States of America. 96 (26): 15268–73. doi:10.1073/pnas.96.26.15268. PMC 24809. PMID 10611374.
  3. “Entrez Gene: SV2A synaptic vesicle glycoprotein 2A”.
  4. Ulloa CM, Towfigh A, Safdieh J (2009). “Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures”. Neuropsychiatric Disease and Treatment. 5: 467–76. doi:10.2147/ndt.s4844. PMC 2747386. PMID 19777068.
Further reading

Further reading


Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH